Inflammation and CV risk: Beyond statins in the treatment of atherosclerosis

Mar. 8, 2016 - Boston, MA, USA - Paul M Ridker

Interindividual variability in response to statins 0:09
Targeting inflammation to lower residual risk 2:14
Reducing hsCRP is as important as reducing LDL-c to lower vascular events 3:55
The NLRP3 inflammasome - central to the postulated mechanism underlying inflammation in CV disease 4:50
Targeting the IL-1beta - IL-6 pathway in two large ongoing clinical trials 5:51
The fundamental question: 'Will lowering inflammation lower CV risk in the absence of change in LDL-c level?' 6:46